Nifty
:
22795.90
Sensex
:
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)
Nifty
Sensex
:
:
22795.90
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 500087 | NSE: CIPLA

NSE BSE
1471.50
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1443.95
  •  1475.30
  •  1438.15
  •  1436.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2918537
  •  42767.12
  •  1702.05
  •  1317.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,19,066.67
  • 23.86
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,18,307.42
  • 0.88%
  • 3.98

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 29.19%
  • 0.54%
  • 14.29%
  • FII
  • DII
  • Others
  • 26.65%
  • 25.79%
  • 3.54%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.55
  • 8.51
  • 5.80

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.27
  • 14.61
  • 6.87

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.08
  • 20.93
  • 17.69

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.04
  • 30.42
  • 30.23

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 3.89
  • 4.04

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.87
  • 16.16
  • 16.48

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
51.05
58.22
64.7
65.81
P/E Ratio
29.21
25.61
23.05
22.66
Revenue
25447
27469
30128
31850
EBITDA
6291
6910
7645
7795
Net Income
4122
4647
5177
5410
ROA
13.3
13.5
13.3
12.5
P/Bk Ratio
4.51
3.97
3.48
3.11
ROE
16.45
16.27
15.78
14.22
FCFF
3192.03
3462.12
3809.98
5129.79
FCFF Yield
2.76
3
3.3
4.44

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
7,072.97
6,603.81
7.10%
7,051.02
6,678.15
5.58%
6,693.94
6,328.89
5.77%
6,163.24
5,739.30
7.39%
Expenses
5,084.05
4,856.28
4.69%
5,165.43
4,944.40
4.47%
4,978.14
4,834.98
2.96%
4,847.38
4,565.56
6.17%
EBITDA
1,988.92
1,747.53
13.81%
1,885.59
1,733.75
8.76%
1,715.80
1,493.91
14.85%
1,315.86
1,173.74
12.11%
EBIDTM
28.12%
26.46%
26.74%
25.96%
25.63%
23.60%
21.35%
20.45%
Other Income
221.61
184.63
20.03%
190.61
176.32
8.10%
160.19
136.29
17.54%
249.33
134.63
85.20%
Interest
14.64
30.10
-51.36%
15.40
25.80
-40.31%
17.95
16.39
9.52%
17.59
34.36
-48.81%
Depreciation
279.80
233.43
19.86%
271.74
290.04
-6.31%
246.68
239.21
3.12%
288.34
346.22
-16.72%
PBT
1,916.09
1,473.81
30.01%
1,789.06
1,594.23
12.22%
1,611.36
1,374.60
17.22%
1,259.26
745.37
68.94%
Tax
332.37
405.30
-17.99%
483.04
438.41
10.18%
435.07
378.02
15.09%
324.86
222.25
46.17%
PAT
1,583.72
1,068.51
48.22%
1,306.02
1,155.82
13.00%
1,176.29
996.58
18.03%
934.40
523.12
78.62%
PATM
22.39%
16.18%
18.52%
17.31%
17.57%
15.75%
15.16%
9.11%
EPS
19.45
13.08
48.70%
16.13
14.01
15.13%
14.58
12.33
18.25%
11.63
6.51
78.65%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
26,981.17
25,774.09
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
Net Sales Growth
6.43%
13.28%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
 
Cost Of Goods Sold
8,790.09
8,819.57
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
Gross Profit
18,191.08
16,954.52
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
GP Margin
67.42%
65.78%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
Total Expenditure
20,075.00
19,483.04
17,762.83
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
Power & Fuel Cost
-
364.84
353.61
331.03
308.26
327.43
335.11
298.82
251.73
245.92
228.28
% Of Sales
-
1.42%
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
Employee Cost
-
4,310.04
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
% Of Sales
-
16.72%
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
Manufacturing Exp.
-
1,779.35
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
% Of Sales
-
6.90%
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
General & Admin Exp.
-
1,673.94
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
% Of Sales
-
6.49%
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
Selling & Distn. Exp.
-
1,724.97
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
% Of Sales
-
6.69%
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
Miscellaneous Exp.
-
810.33
619.43
565.55
508.00
692.12
855.40
968.98
645.54
657.29
738.87
% Of Sales
-
3.14%
2.72%
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
4.39%
EBITDA
6,906.17
6,291.05
4,990.29
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
EBITDA Margin
25.60%
24.41%
21.93%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
19.05%
Other Income
821.74
746.57
512.13
321.73
269.77
369.38
476.57
357.65
228.69
208.21
165.55
Interest
65.58
89.88
109.54
106.35
160.70
197.36
168.43
114.23
159.38
206.63
168.29
Depreciation
1,086.56
1,051.02
1,172.11
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
PBT
6,575.77
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
Tax
1,575.34
1,546.59
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
331.59
400.03
Tax Rate
23.96%
27.12%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
PAT
5,000.43
4,123.14
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
PAT before Minority Interest
5,003.22
4,155.31
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
Minority Interest
2.79
-32.17
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
PAT Margin
18.53%
16.00%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
PAT Growth
33.56%
47.02%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
 
EPS
62.04
51.16
34.80
31.38
30.00
19.78
19.17
17.53
12.57
17.02
14.96

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
26,706.43
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
Share Capital
161.47
161.43
161.36
161.29
161.25
161.14
161.02
160.90
160.68
160.59
Total Reserves
26,458.42
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
Non-Current Liabilities
81.92
183.53
621.70
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
Secured Loans
0.00
332.46
376.20
355.32
304.74
47.70
0.00
0.00
207.00
287.09
Unsecured Loans
0.00
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
Long Term Provisions
129.26
102.16
100.22
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
Current Liabilities
5,245.77
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
Trade Payables
2,473.98
2,534.52
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
Other Current Liabilities
890.98
1,007.60
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
654.55
Short Term Borrowings
247.02
187.90
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
Short Term Provisions
1,633.79
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
Total Liabilities
32,130.02
28,930.34
26,651.95
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
Net Block
9,493.61
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
Gross Block
18,161.28
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
Accumulated Depreciation
8,574.10
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
Non Current Assets
12,688.61
11,731.79
11,924.75
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
Capital Work in Progress
1,152.72
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
Non Current Investment
642.21
572.52
355.63
545.43
578.80
490.20
157.66
137.36
176.35
249.76
Long Term Loans & Adv.
838.53
845.11
736.39
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
Other Non Current Assets
447.93
60.38
383.22
102.51
77.61
166.82
255.71
210.06
176.54
168.88
Current Assets
19,392.45
16,805.06
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
Current Investments
4,807.01
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
Inventories
5,237.95
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
Sundry Debtors
4,770.66
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
Cash & Bank
874.97
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
Other Current Assets
3,701.86
373.99
305.56
347.54
1,416.84
1,566.48
1,599.13
1,226.01
1,223.17
858.67
Short Term Loans & Adv.
3,134.22
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
Net Current Assets
14,146.68
11,771.79
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
Total Assets
32,081.06
28,536.85
26,635.58
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
4,133.91
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
PBT
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
Adjustment
640.77
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
Changes in Working Capital
-806.10
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
Cash after chg. in Working capital
5,731.39
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,597.48
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,988.03
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
Net Fixed Assets
-373.49
-600.42
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
Net Investments
-1,884.41
-935.67
-1,124.06
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
Others
-730.13
-852.42
-425.89
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
Cash from Financing Activity
-1,200.43
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
Net Cash Inflow / Outflow
-54.55
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
397.06
Opening Cash & Equivalents
561.33
658.11
790.43
649.13
508.36
853.47
610.35
858.15
545.84
175.76
Closing Cash & Equivalent
512.34
561.33
658.11
790.43
742.38
508.36
853.46
610.35
858.15
564.26

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
329.72
289.24
257.78
226.73
194.85
185.62
175.92
155.15
142.23
133.38
ROA
13.59%
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
ROE
16.63%
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
ROCE
22.77%
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
Fixed Asset Turnover
2.00
1.81
1.82
1.85
1.89
1.79
1.25
1.36
1.40
1.26
Receivable days
45.49
44.13
42.19
47.44
54.10
55.36
68.17
61.60
57.62
57.94
Inventory Days
53.56
61.98
61.53
58.49
56.12
61.13
90.71
91.41
100.43
106.36
Payable days
103.64
111.52
98.28
107.95
128.84
59.02
57.37
46.96
51.51
52.17
Cash Conversion Cycle
-4.58
-5.41
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
112.14
Total Debt/Equity
0.01
0.02
0.04
0.10
0.18
0.29
0.29
0.33
0.46
0.16
Interest Cover
64.44
37.87
33.85
21.47
12.04
13.34
15.61
8.67
9.36
10.83

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Cipla gets USFDA’s final nod for Nilotinib Capsules
    21st Feb 2025, 10:18 AM

    Nilotinib is an oncology category product in capsule form for oral consumption

    Read More
  • USFDA concludes cGMP inspection at analytical testing facility of Cipla’s arm
    21st Feb 2025, 10:07 AM

    On conclusion of the inspection, Sitec received two observations in Form 483

    Read More
  • USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated
    10th Feb 2025, 10:20 AM

    USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024

    Read More
  • Cipla to invest in Cipla Medpro South Africa Proprietary
    3rd Feb 2025, 17:23 PM

    The investment is expected to be completed on or before February 28, 2025

    Read More
  • Cipla reports 47% rise in Q3 consolidated net profit
    28th Jan 2025, 16:42 PM

    Total consolidated income of the company increased by 7.46% at Rs 7294.58 crore for Q3FY25

    Read More
  • Cipla - Quarterly Results
    28th Jan 2025, 14:00 PM

    Read More
  • Cipla’s arm gets one observation for Goa facility
    21st Jan 2025, 11:27 AM

    USFDA has conducted an inspection at the manufacturing facility of Medispray Laboratories

    Read More
  • Cipla launches mobile application for asthma screening
    7th Jan 2025, 14:56 PM

    The mobile application is designed to enable the first line of screening for asthma in India

    Read More
  • Cipla secures approval for distribution, marketing of Afrezza Inhalation Powder in India
    13th Dec 2024, 12:39 PM

    This is the first and only noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.